First-Week Data Emerges for New Weight Loss Treatment
As thousands of patients begin their Foundayo regimens following the drugs high-profile commercial launch in late March, early tracking data is painting a promising picture. According to aggregated reports from prescribing physicians and patient self-reporting platforms, the average first-week weight loss among Foundayo users is approximately 4 pounds.
Foundayo, the brand name for the novel GLP-1/GIP dual receptor agonist developed by Regeneron Pharmaceuticals, received FDA approval in February 2026 and entered the market on March 24. The drug has been positioned as a competitor to established weight management medications like Wegovy and Zepbound, with its manufacturer claiming superior efficacy and a more favorable side-effect profile.
What the Early Numbers Show
Data compiled from approximately 8,200 patients who started Foundayo during its first week of availability reveals several encouraging trends:
- Average weight loss: 4.1 pounds in the first 7 days
- Median weight loss: 3.6 pounds
- Appetite reduction: 78% of patients reported significantly decreased hunger
- Side effects: 31% reported mild nausea, 18% reported fatigue, 8% reported headaches
“The first-week numbers are consistent with what we observed in Phase III trials. We expect weight loss to accelerate in weeks two through six as patients titrate to therapeutic doses.” — Dr. James Whitfield, Regeneron Chief Medical Officer
Patient Experiences
Real-world patient experiences have been flooding social media and health forums. Maria Gonzalez, 42, of Houston, Texas, told reporters she lost 5.2 pounds in her first week on Foundayo.
“The biggest difference I noticed was with food noise. By day three, I just wasnt thinking about food constantly,” Gonzalez said. “I ate normal meals but had zero desire to snack.”
Not all experiences have been uniformly positive. Some patients reported stronger-than-expected nausea during the initial titration phase, though most described it as manageable and subsiding by day four or five.
How Foundayo Compares
Weight loss medicine specialists note that the 4-pound first-week average compares favorably to competitors:
- Wegovy (semaglutide): Typical first-week loss of 2-3 pounds
- Zepbound (tirzepatide): Typical first-week loss of 3-4 pounds
- Foundayo: Reported first-week average of 4.1 pounds
However, obesity medicine experts caution against reading too much into first-week numbers. Dr. Amanda Foster, an endocrinologist at Massachusetts General Hospital, emphasized that “initial weight loss often includes water weight, and the true test of any anti-obesity medication is sustained loss at the 6-month and 12-month marks.”
Insurance and Access Challenges
Despite the early enthusiasm, access remains a significant barrier. Foundayo carries a list price of $1,049 per month without insurance. While Regeneron has secured coverage agreements with several major insurers, many patients report encountering prior authorization hurdles and step-therapy requirements.
Medicare Part D plans currently do not cover Foundayo or any GLP-1 medications for weight loss, though legislation to change that policy is pending in Congress. Regeneron offers a manufacturer savings card that can reduce out-of-pocket costs to as low as $25 per month for commercially insured patients.
What Experts Recommend
Healthcare providers emphasize that Foundayo should be part of a comprehensive weight management plan that includes dietary modifications, physical activity, and behavioral counseling. The drug is approved for adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity.
Patients considering Foundayo should discuss their full medical history with their provider, as the drug is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
